Amarin Corporation

AMRN · Nasdaq · Ireland

Share price · AMRN

$11.26-2.87 (-20.31%) 3M

close as of 2026-11-18 · 24h delayed · vol 95K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AMRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026+6.7%
  2. 8 Sep 2026+4.5%
  3. 4 Jun 2026-5.0%
  4. 10 Mar 2026+9.5%
  5. 25 Feb 2026-9.5%
  6. 8 Jan 2026+16.9%
  7. 8 Dec 2025-9.8%

Share of unusual movement by asset

For each asset, the share of AMRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Icosapent Ethyl (Vascepa)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—33%
Sessions with no dated event—65%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
Omega-3 fatty acid (EPA)Small molecule
Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 October 2026Topline resultIcosapent EthylEMT2 Phase 3 trial results: primary PFS endpoint not met, OS improved

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$40M$4.2M$157M+ $167M short-term inv.—$9.2M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$42M$4.8M$144M+ $171M short-term inv.$7.7M$6.6M operating cash flowreport ↗
2026-Q1$45M$4.7M$131M+ $177M short-term inv.$11M$6.4M operating cash flowreport ↗
2025-Q3$50M$4.2M$123M+ $164M short-term inv.$7.7M-$13M operating cash flowreport ↗
2025-Q2$73M$4.9M$148M+ $151M short-term inv.$14M$17M operating cash flowreport ↗
2025-Q1$42M$5.3M$120M+ $162M short-term inv.$16M-$12M operating cash flowreport ↗
2024-Q3$42M$4.5M$157M+ $149M short-term inv.$25M-$2.4M operating cash flowreport ↗
2024-Q2$67M$4.8M$216M+ $91M short-term inv.—-$2.8M operating cash flowreport ↗
2024-Q1$57M$5.6M$214M+ $94M short-term inv.$9.9M-$13M operating cash flowreport ↗
2023-Q3$66M$5.1M$271M+ $50M short-term inv.$19M$7.3M operating cash flowreport ↗
2023-Q2$80M$5.6M$233M+ $80M short-term inv.$18M$7.2M operating cash flowreport ↗
2023-Q1$86M$5.7M$191M+ $113M short-term inv.$16M-$7.0M operating cash flowreport ↗
2022-Q3$90M$5.8M$241M+ $63M short-term inv.$5.1M-$18M operating cash flowreport ↗
2022-Q2$94M$9.4M$228M+ $85M short-term inv.$70M-$65M operating cash flowreport ↗
2022-Q1$95M$10M$219M+ $143M short-term inv.$32M-$99M operating cash flowreport ↗
2021-Q3$142M$7.8M$223M+ $256M short-term inv.$13M-$4.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$214M$20M$135M+ $168M short-term inv.$9.7M$6.7M operating cash flowreport ↗

Amarin reported full-year 2025 revenue of $213.65M, down 6.5% YoY from $228.61M. R&D spend was $19.81M, down 5.1% YoY, and cash and equivalents totaled $134.66M, with a net loss of $38.8M.

The company highlighted a long-term license and supply agreement with Recordati to commercialize VAZKEPA across Europe, sustained U.S. market leadership for the VASCEPA franchise, and 45 publications supporting the product’s scientific evidence base. Management said restructuring initiatives had delivered $31M of an expected $70M in cost savings, with total restructuring costs projected at $37–$40M, and positioned the company to generate positive cash flow for the full year ahead.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$229M$21M$121M+ $173M short-term inv.$21M-$31M operating cash flowreport ↗
2023-FY$307M$22M$199M+ $121M short-term inv.$15M$6.9M operating cash flowreport ↗
2022-FY$369M$30M$218M+ $92M short-term inv.$26M-$180M operating cash flowreport ↗
2021-FY$583M$29M$219M+ $235M short-term inv.—-$67M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-01Fishman Peter L. · SVP, CFOOption exercise313——Form 4
2026-08-01Fishman Peter L. · SVP, CFOTax withholding155$14.26$2KForm 4
2026-08-01Fishman Peter L. · SVP, CFOAward / grant (derivative)313——Form 4
2026-07-01Provoost Jonathan · EVP, Chief Legal OfficerOption exercise3,688——Form 4
2026-07-01Ketchum Steven B · EVP, Chief Scientific OfficerOption exercise3,688——Form 4
2026-07-01Keenan David Paul · EVP, Chief Operating OfficerOption exercise3,688——Form 4
2026-07-01Fishman Peter L. · SVP, CFOOption exercise2,447——Form 4
2026-07-01Provoost Jonathan · EVP, Chief Legal OfficerTax withholding1,264$15.94$20KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 4.6M shares ($57.1M, 21.9% of shares outstanding).

#InstitutionSharesValue
1Sarissa Capital Management LP1,673,395$24.2M
2Kynam Capital Management, LP472,382$6.8M
3MILLENNIUM MANAGEMENT LLC300,536$4.3M
4MORGAN STANLEY293,172$4.2M
5Point72 Asset Management, L.P.240,761$3.5M
6Waterfront Wealth Inc.203,338$2.9M
7Eversept Partners, LP147,715$2.1M
8TWO SIGMA INVESTMENTS, LP107,542$1.6M
9CITADEL ADVISORS LLC80,575$1.2M
10BNP PARIBAS FINANCIAL MARKETS75,503$1.1M
11LCM Capital Management Inc43,462$628K
12SUSQUEHANNA INTERNATIONAL GROUP, LLP37,667$545K
13STATE STREET CORP24,949$361K
14Bleakley Financial Group, LLC23,564$341K
15RENAISSANCE TECHNOLOGIES LLC19,256$278K